35980-77-9

Basic information

• Product Name: 2-(4-morpholinyl)-4-pyridinylamine
• Synonyms: 2-(4-morpholinyl)-4-pyridinylamine;2-MORPHOLIN-4-YLPYRIDIN-4-AMINE;2-morpholin-4-yl-pyridin-4-ylamine;2-Morpholinopyridin-4-aMine;2-Mrpholinopyridin-4-amine
• CAS NO: 35980-77-9
• Molecular Formula: C₉H₁₃N₃O
• Molecular Weight: 179.22
• Mol File: 35980-77-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 414.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.208±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.35±0.10(Predicted)
• CAS DataBase Reference: 2-(4-morpholinyl)-4-pyridinylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-morpholinyl)-4-pyridinylamine(35980-77-9)
• EPA Substance Registry System: 2-(4-morpholinyl)-4-pyridinylamine(35980-77-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 35980-77-9(Hazardous Substances Data)

Usage

General Description

2-(4-morpholinyl)-4-pyridinylamine, also known as MP4A, is a chemical compound that belongs to the class of organic compounds called anilines. It is a colorless, solid substance that is soluble in water and has a molecular weight of 168.208 g/mol. MP4A is used in the pharmaceutical industry as an intermediate for the synthesis of various drugs and as a building block in the production of novel chemical entities. It has also been studied for its potential therapeutic properties, especially in the treatment of certain types of cancer and neurological disorders. Additionally, MP4A is known to act as a ligand for various receptors, making it an important tool in drug discovery and development. However, like all chemical substances, MP4A should be handled with caution and in accordance with proper safety protocols.

Upstream product

• 35981-62-5 2-(N-morpholinyl)-4-nitropyridine N-oxide 
• 14432-16-7 2-chloro-4-nitropyridine-N-oxide 
• 110-91-8 morpholine 
• 14432-12-3 4-Amino-2-chloropyridine 
• 1285603-68-0 6-chloro-4-morpholin-4-yl-pyridin-2-amine 
• 23056-36-2 2-chloro-4-nitropyridine 
• 848144-27-4 4-(4-nitropyridin-2-yl)morpholine 
• 22918-01-0 2-bromo-4-chloropyridine 
• 7598-35-8 2-bromo-4-aminopyridine 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 22282-70-8 2-fluoro-4-iodopyridine 

Downstream Products

• 36265-14-2 bis-aziridin-1-yl-phosphinic acid 2-morpholin-4-yl-pyridin-4-ylamide 
• 1040377-12-5 4-(4-bromopyridin-2-yl)morpholine 
• 1354286-33-1 4-(4-(5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-ylamino)-6-morpholinopyridin-3-yl)phenol 
• 1354286-87-5 N-(5-(5-(difluoromethyl)-2-fluorophenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 
• 1354286-92-2 N-(5-(3-(difluoromethyl)-4-fluorophenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 
• 1354286-94-4 N-(5-(4-(difluoromethyl)-3-fluorophenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 
• 1354289-42-1 5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-amine 
• 1354287-52-7 N-(5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-yl)-5,7-difluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-amine 
• 1354287-56-1 1-(4-(5-(4-(difluoromethoxy)-3-fluorophenyl)-2-morpholinopyridin-4-ylamino)-5,7-difluoro-3-methylquinolin-2-yl)-4,4-dimethylpyrrolidin-2-one 
• 1354287-60-7 5,7-difluoro-3-methyl-N-(2-morpholino-5-(3-(trifluoromethyl)phenyl)pyridin-4-yl)-2-(pyridin-2-yl)quinolin-4-amine 
• 1354287-62-9 5,7-difluoro-3-methyl-N-(2-morpholino-5-(4-(trifluoromethyl)phenyl)pyridin-4-yl)-2-(pyridin-2-yl)quinolin-4-amine 
• 1354287-68-5 5,7-difluoro-3-methyl-N-(2-morpholino-5-(3-(trifluoromethoxy)phenyl)pyridin-4-yl)-2-(pyridin-2-yl)quinolin-4-amine 
• 1354287-70-9 5,7-difluoro-3-methyl-N-(2-morpholino-5-(4-(trifluoromethoxy)phenyl)pyridin-4-yl)-2-(pyridin-2-yl)quinolin-4-amine 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

TGF-betaR1 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.

Streamlined Synthesis of Diaminopyridines by Pd-Catalyzed Ammonia Coupling with Deactivated Amino-Chloropyridines

An efficient and cost-effective two-step synthesis of diaminopyridines, fundamental building blocks of biologically active compounds, is reported. The advantages over previously reported routes include cost and wider availability of the bromo-chloropyridine starting materials and the straightforward accessibility to an extended array of diaminopyridine regioisomers. The key enabler of this synthetic strategy is the development of an unprecedented palladium-catalyzed coupling reaction of ammonia with chloropyridines deactivated by the presence of an alkylamino substituent. The coupling reaction was accomplished with very low catalyst loadings under remarkably mild reaction conditions, making the system particularly suitable for both academic and industrial applications. The utility of this methodology is exemplified by the application to the synthesis of highly relevant scaffolds, including the synthetic intermediates of the marketed drugs Ribociclib and Palbociclib.